Transcept Pharmaceuticals to Present at the BMO Capital Markets 2008 Focus on Healthcare...

* Reuters is not responsible for the content in this press release.

Wed Jul 23, 2008 9:01am EDT 

Transcept Pharmaceuticals to Present at the BMO Capital Markets 2008 Focus on
Healthcare Conference

    PT. RICHMOND, Calif., July 23 /PRNewswire/ -- Transcept Pharmaceuticals,
Inc. today announced that Glenn A. Oclassen, President & Chief Executive
Officer, will present at the BMO Capital Markets 2008 Focus on Healthcare
Conference at the Millennium Broadway Hotel in New York City on Wednesday,
August 6, 2008 at 11:45 AM Eastern Time.
    About Transcept Pharmaceuticals
    Transcept Pharmaceuticals, Inc. is a specialty pharmaceutical company
deriving significant new patient benefits from proven CNS drugs. Transcept
development projects leverage new understanding of CNS conditions to provide
additional uses and enhanced clinical benefits for existing active agents. The
lead Transcept product candidate, Intermezzo(R) (zolpidem tartrate sublingual
lozenge), is a low dose formulation of zolpidem for the treatment of insomnia
in patients who awaken in the middle of the night and have difficulty
returning to sleep. Phase 3 clinical trials have been completed for
Intermezzo(R) and Transcept plans to submit an NDA in the third quarter of
2008. Transcept is also developing TO-2060, a novel, fixed-dose combination of
olanzapine and ondansetron for the treatment of dopamine associated
psychiatric disorders.  For further information, please visit the Company's
website at: http://www.transcept.com.
     Contacts:

     Transcept Pharmaceuticals, Inc.       The Ruth Group
     Michael Gill                          Investors / Media
     Director of Communications            Stephanie Carrington / Jason Rando
     (510) 215-3575                        (646) 536-7017 / 7025
     mgill@transcept.com                   scarrington@theruthgroup.com
                                           jrando@theruthgroup.com

SOURCE  Transcept Pharmaceuticals, Inc.

Michael Gill, Director of Communications of Transcept Pharmaceuticals, Inc.,
+1-510-215-3575, mgill@transcept.com; or Investors, Stephanie Carrington,
+1-646-536-7017, scarrington@theruthgroup.com, or Media, Jason Rando,
+1-646-536-7025, jrando@theruthgroup.com, both of The Ruth Group for Transcept
Pharmaceuticals, Inc.
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.